Plain Language Summaries is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • How to
  • FAQs
  • Publications
  • Advisory Panel
    • Plain Language Advisors
    • Scientific Content Advisors
  • Supporters
  • Blog
  • About us
  • Contact Us

overall survival

27th May 2025

Plain language summary: The IPSOS study comparing atezolizumab versus standard chemotherapy for non-small cell lung cancer patients unsuitable for platinum treatment

26th Mar 2025

Plain language summary of prostate-specific antigen (PSA) response to darolutamide in metastatic hormone-sensitive prostate cancer and its effect on treatment outcomes in the ARASENS trial

23rd Sep 2024

Prostate-specific antigen levels and quality of life in advanced prostate cancer patients treated with apalutamide: a plain language summary of the SPARTAN and TITAN trials

This summary describes the results from an additional (or post hoc) analysis of the TITAN study. The TITAN study looked at whether the prostate cancer treatment apalutamide could be used to treat individuals with metastatic castration-sensitive prostate cancer (or mCSPC).
22nd Jan 2024

The TITAN study: a plain language summary looking at how PSA decline with apalutamide therapy is associated with longer survival and improved outcomes in people with metastatic prostate cancer

This is a summary of a research article originally published in the Journal of Urology. The PROSPER study involved men who had a type of advanced prostate cancer called non-metastatic castration-resistant prostate cancer (nmCRPC). In patients with nmCRPC, their prostate cancer keeps growing even after traditional hormone treatments. In these patients, rising prostate-specific antigen (PSA) levels suggest that cancer is active but CT and bone scans show that it has not spread to other parts of the body. Everyone in this study received androgen deprivation therapy (ADT) either with the medicine enzalutamide or a placebo. Enzalutamide is a medicine that can slow or stop androgens, such as testosterone, from making prostate cancer grow. The main results of the PROSPER study showed that patients with nmCRPC treated with enzalutamide and ADT lived longer than patients treated with placebo and ADT. In this study, researchers wanted to know if the findings were different depending on how much patients’ PSA level declined after enzalutamide treatment. Researchers also wanted to know if this made a difference in how long patients lived without the cancer spreading to other parts of their body
10th Aug 2023

A plain language summary looking at whether declines in prostate-specific antigen level indicates how long patients with advanced prostate cancer will live when treated with enzalutamide

12th Apr 2023

Plain Language Summary: a real-world database analysis on prolonging the life of people with metastatic breast cancer in routine clinical practice by adding palbociclib to an aromatase inhibitor

Copyright © 2026 · Plain Language Summaries · Terms and conditions · Privacy policy · Cookie policy